Tag: UCART22
Cellectis Announces First Patient Dosing in Europe with In-house Manufactured UCART22 Product Candidate
By Hector Chaunu Published on 04/12/2023 at 07:21 Photo credit © Cellectis – Ramon Martinez (Boursier.com) — Cellectis…
Cellectis: UCART22 has been administered to a first patient for the treatment of acute lymphoblastic leukemia
(Boursier.com) — Cellectis a clinical-stage biotechnology company that uses its pioneering TALEN genome-editing technology to develop innovative therapies for the treatment of serious diseases, today announces that its in-house manufactured…